Immunotherapy of lung cancer: An update [PDF]
, 2006 In Germany lung cancer is the leading cause of cancer-associated death in men. Surgery, chemotherapy and radiation may enhance survival of patients suffering from lung cancer but the enhancement is typically transient and mostly absent with advanced ...
Aman MJ +36 more
core +1 more source
Adoptive Immunotherapy in Postoperative Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. [PDF]
PLoS ONE, 2016 Adoptive immunotherapy (AI) has been applied in the treatment of non-small-cell lung cancer (NSCLC) patients, but the value of postoperative AI has been inconclusive largely as a result of the small number of patients included in each study. We performed
Yuan Zeng +7 more
doaj +1 more source
Frontiers in Pharmacology, 2021 So far, immunotherapy has been shown to have impressive effects on different cancers in clinical trials. All those immunotherapies are generally derived from three main therapeutic approaches: immune checkpoint inhibitors, immune cell vaccination, and ...
Fanming Kong +7 more
doaj +1 more source
New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer [PDF]
, 2012 A summit on cellular therapy for cancer discussed and presented advances related to the use of adoptive cellular therapy for melanoma and other cancers. The summit revealed that this field is advancing rapidly.
A Lundqvist +48 more
core +4 more sources
Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy [PDF]
, 2020 Chimeric antigen receptor (CAR) T-cell therapy has produced remarkable anti-tumor responses in patients with B-cell malignancies. However, clonal kinetics and transcriptional programs that regulate the fate of CAR-T cells after infusion remain poorly ...
Adair, Jennifer E. +16 more
core +1 more source
Adoptive T-Cell Immunotherapy [PDF]
, 2015 Epstein-Barr virus (EBV) is associated with a range of malignancies involving B cells, T cells, natural killer (NK) cells, epithelial cells, and smooth muscle. All of these are associated with the latent life cycles of EBV, but the pattern of latency-associated viral antigens expressed in tumor cells depends on the type of tumor.
Cliona M. Rooney, Stephen Gottschalk
openaire +3 more sources
Biological therapy in the treatment of melanoma [PDF]
, 2018 Melanoma is one of the most aggressive tumors and its incidence is on the rise. The low rates of survival in metastatic melanoma has led to the development of new drugs for this type of patient, such as biological therapy which has shown remarkable ...
Benea, Vasile +8 more
core +3 more sources
In vivo application of recombinant interleukin 2 in the immunotherapy of established cytomegalovirus infection [PDF]
, 1987 We have shown in a murine model system for cytomegalovirus (CMV) disease in the immunocompromised host that in vivo application of recombinant human IL-2 (rhIL-2) can enhance the antiviral effect of a limited number of CD8+T lymphocytes, not only in ...
Koszinowski, Ulrich H. +2 more
core +3 more sources
A biomathematical model of tumor response to radioimmunotherapy with $α$PDL1 and $α$CTLA4 [PDF]
IEEE/ACM Transactions on Computational Biology and Bioinformatics
2023;20:808-821, 2021 There is evidence of synergy between radiotherapy and immunotherapy. Radiotherapy can increase liberation of tumor antigens, causing activation of antitumor T-cells. This effect can be boosted with immunotherapy. Radioimmunotherapy has potential to increase tumor control rates.
arxiv +1 more source
Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA–peptide tetramers [PDF]
, 2005 Stem cell transplantation is used widely in the management of a range of diseases of the hemopoietic system. Patients are immunosuppressed profoundly in the early posttransplant period, and reactivation of cytomegalovirus (CMV) remains a significant ...
Assenmacher, Mario +15 more
core +5 more sources